IgE, Allergic Diseases, and Omalizumab

E-ISSN： 1873-4286|12|30|3929-3944

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.12, Iss.30, 2006-10, pp. : 3929-3944

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-IgE Monoclonal Antibody (Omalizumab) in the Treatment of Atopic Asthma and Allergic Respiratory Diseases

Current Drug Targets. Inflammation & Allergy, Vol. 3, Iss. 3, 2004-09 ,pp. : 227-229

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma

By Chung K Fan

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Novel anti-IgE monoclonal antibody promising against allergic diseases

Inpharma, Vol. 1, Iss. 1232, 2000-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 7, Iss. 1, 2008-03 ,pp. : 27-31

Bentham Science Publishers

Access to resources Recommend Favorite

IgE modulation in asthma

By Dent Gordon

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 10, 2003-10 ,pp. : 1607-1617

Informa Healthcare

Access to resources Recommend Favorite